Marshwinds Advisory Co. trimmed its stake in Pfizer Inc. (NYSE:PFE) by 2.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 120,125 shares of the biopharmaceutical company’s stock after selling 2,643 shares during the period. Pfizer comprises 2.4% of Marshwinds Advisory Co.’s holdings, making the stock its 6th biggest holding. Marshwinds Advisory Co.’s holdings in Pfizer were worth $5,294,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors also recently added to or reduced their stakes in the business. Massachusetts Financial Services Co. MA lifted its position in shares of Pfizer by 0.3% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 61,881,280 shares of the biopharmaceutical company’s stock worth $2,245,053,000 after purchasing an additional 160,730 shares during the period. Morgan Stanley lifted its position in shares of Pfizer by 2.5% in the 2nd quarter. Morgan Stanley now owns 54,367,234 shares of the biopharmaceutical company’s stock worth $1,972,442,000 after purchasing an additional 1,345,528 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Pfizer by 15.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 54,233,658 shares of the biopharmaceutical company’s stock worth $1,967,651,000 after purchasing an additional 7,059,171 shares during the period. Fisher Asset Management LLC lifted its position in shares of Pfizer by 4.4% in the 2nd quarter. Fisher Asset Management LLC now owns 39,445,117 shares of the biopharmaceutical company’s stock worth $1,431,069,000 after purchasing an additional 1,671,311 shares during the period. Finally, LSV Asset Management raised its stake in shares of Pfizer by 2.7% during the 2nd quarter. LSV Asset Management now owns 36,774,591 shares of the biopharmaceutical company’s stock worth $1,334,182,000 after acquiring an additional 973,497 shares in the last quarter. 69.30% of the stock is owned by institutional investors.
Shares of Pfizer stock opened at $44.16 on Thursday. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.47. Pfizer Inc. has a 12-month low of $33.20 and a 12-month high of $46.47. The company has a market cap of $261.99 billion, a price-to-earnings ratio of 16.66, a P/E/G ratio of 2.19 and a beta of 0.88.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.03. Pfizer had a net margin of 44.63% and a return on equity of 25.26%. The business had revenue of $13.30 billion for the quarter, compared to analyst estimates of $13.53 billion. During the same quarter in the prior year, the business posted $0.67 EPS. Pfizer’s revenue for the quarter was up 1.0% compared to the same quarter last year. Research analysts forecast that Pfizer Inc. will post 3 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Monday, December 3rd. Shareholders of record on Friday, November 9th were paid a dividend of $0.34 per share. The ex-dividend date was Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a yield of 3.08%. Pfizer’s payout ratio is 51.32%.
In related news, major shareholder Pfizer Inc purchased 55,556 shares of the business’s stock in a transaction on Monday, October 15th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $1,000,008.00. Following the purchase, the insider now owns 21,976,484 shares of the company’s stock, valued at approximately $395,576,712. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.
PFE has been the subject of several recent analyst reports. Deutsche Bank set a $45.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, August 21st. Morgan Stanley set a $45.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Thursday, August 23rd. Barclays boosted their price objective on shares of Pfizer from $38.00 to $40.00 and gave the stock a “neutral” rating in a research note on Thursday, August 23rd. JPMorgan Chase & Co. reiterated a “buy” rating and set a $42.00 price objective on shares of Pfizer in a research note on Thursday, August 23rd. Finally, Cantor Fitzgerald set a $45.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, August 27th. Two equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have given a buy rating to the company’s stock. Pfizer presently has a consensus rating of “Hold” and a consensus target price of $43.27.
ILLEGAL ACTIVITY WARNING: “Marshwinds Advisory Co. Has $5.29 Million Holdings in Pfizer Inc. (PFE)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/12/13/marshwinds-advisory-co-has-5-29-million-holdings-in-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Read More: How does a 12b-1 fee affect fund performance?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.